Skip to main content
. 2011 Jul;163(6):1122–1130. doi: 10.1111/j.1476-5381.2010.01167.x

Figure 1.

Figure 1

Angiotensin II type 1 receptor blockers (ARBs) improve vascular remodelling and metabolic syndrome associated with anti-atherogenic effects, and reduce atrial fibrillation, resulting in reduction of onset of stroke. AF, atrial fibrillation; DM, diabetes mellitus; TIA, transient cerebral ischaemic attack.